Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider David Malcom Rodman Sells 55,771 Shares of Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 55,771 shares of the firm’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $15.76, for a total value of $878,950.96. Following the completion of the transaction, the insider now directly owns 116,704 shares of the company’s stock, valued at $1,839,255.04. The trade was a 32.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Mineralys Therapeutics Stock Performance

Mineralys Therapeutics stock opened at $12.40 on Friday. Mineralys Therapeutics, Inc. has a fifty-two week low of $8.24 and a fifty-two week high of $18.38. The stock has a fifty day moving average of $11.90 and a two-hundred day moving average of $12.28. The company has a market capitalization of $778.53 million, a price-to-earnings ratio of -3.41 and a beta of -0.39.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its earnings results on Wednesday, February 12th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. On average, analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on MLYS. Guggenheim reissued a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, February 24th. HC Wainwright increased their price objective on shares of Mineralys Therapeutics from $30.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, The Goldman Sachs Group cut their target price on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, February 13th.

Hedge Funds Weigh In On Mineralys Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new stake in Mineralys Therapeutics in the 4th quarter worth approximately $48,000. ProShare Advisors LLC purchased a new stake in shares of Mineralys Therapeutics in the fourth quarter valued at $128,000. China Universal Asset Management Co. Ltd. increased its stake in Mineralys Therapeutics by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company’s stock valued at $130,000 after purchasing an additional 989 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Mineralys Therapeutics during the fourth quarter worth about $145,000. Finally, PDT Partners LLC acquired a new stake in Mineralys Therapeutics in the 3rd quarter worth about $148,000. Hedge funds and other institutional investors own 84.46% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.